trial · primary record
Brelovitug 300 mg
Chronic Hepatitis D Infection
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 150 |
| Primary completion | 2029-09 |
| Primary endpoint | Percentage of participants with a composite endpoint |
| Registry ID | NCT06907290 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:38.558Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06907290
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.